Short Interest in ProPhase Labs, Inc. (NASDAQ:PRPH) Decreases By 16.9%

ProPhase Labs, Inc. (NASDAQ:PRPH - Get Free Report) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 248,200 shares, a decrease of 16.9% from the February 29th total of 298,500 shares. Based on an average daily volume of 26,100 shares, the short-interest ratio is presently 9.5 days. Approximately 1.8% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $11.00 price target on shares of ProPhase Labs in a report on Wednesday, February 21st.

Hedge Funds Weigh In On ProPhase Labs

Institutional investors and hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC raised its stake in ProPhase Labs by 7.9% during the third quarter. Cubist Systematic Strategies LLC now owns 16,537 shares of the company's stock worth $187,000 after purchasing an additional 1,205 shares during the period. Dimensional Fund Advisors LP raised its stake in ProPhase Labs by 7.9% during the third quarter. Dimensional Fund Advisors LP now owns 24,841 shares of the company's stock worth $280,000 after purchasing an additional 1,820 shares during the period. Bank of America Corp DE raised its stake in ProPhase Labs by 8.0% during the fourth quarter. Bank of America Corp DE now owns 29,273 shares of the company's stock worth $282,000 after purchasing an additional 2,172 shares during the period. First Trust Advisors LP increased its position in shares of ProPhase Labs by 8.3% in the first quarter. First Trust Advisors LP now owns 35,105 shares of the company's stock worth $268,000 after acquiring an additional 2,678 shares in the last quarter. Finally, State Street Corp increased its position in shares of ProPhase Labs by 8.1% in the first quarter. State Street Corp now owns 40,163 shares of the company's stock worth $306,000 after acquiring an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own 9.45% of the company's stock.

ProPhase Labs Trading Up 3.4 %

Shares of PRPH traded up $0.21 on Friday, hitting $6.47. 16,102 shares of the stock traded hands, compared to its average volume of 26,907. The company has a quick ratio of 2.73, a current ratio of 3.04 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $116.78 million, a P/E ratio of -11.76 and a beta of -0.34. The stock's 50 day moving average is $5.12 and its two-hundred day moving average is $4.79. ProPhase Labs has a 1 year low of $4.05 and a 1 year high of $9.94.

About ProPhase Labs

ProPhase Labs, Inc engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.